A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/2 Recruiting
200 enrolled
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
MK-3475-G21
Phase 1/2 Recruiting
20 enrolled
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Phase 2 Recruiting
80 enrolled
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/2 Recruiting
70 enrolled
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Recruiting
60 enrolled
OPAL
Phase 1/2 Recruiting
144 enrolled
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
Phase 2 Recruiting
40 enrolled
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Phase 2 Recruiting
44 enrolled
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Recruiting
1,029 enrolled
Collection of Tissue Samples for Cancer Research
Recruiting
5,000 enrolled
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Recruiting
1,000 enrolled
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Recruiting
1,100 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Phase 2 Recruiting
100 enrolled
EPCOREâ„¢FL-2
Phase 3 Recruiting
1,095 enrolled
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Phase NA Recruiting
24 enrolled
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Phase 2 Recruiting
40 enrolled
Study of CAR-T Therapy in Older Patients
Recruiting
154 enrolled
Sample Collection and Tracking for the Developmental Therapeutics Clinic
Recruiting
3,000 enrolled
TERZO
Phase 3 Recruiting
124 enrolled
U96-CAR-T-Cells For R/R B-ALL
Phase 1 Recruiting
30 enrolled
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Phase NA Recruiting
400 enrolled
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Phase 1 Recruiting
42 enrolled
GLOBRYTE
Phase 3 Recruiting
182 enrolled
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 1 Recruiting
50 enrolled
QUADvance
Phase 1/2 Recruiting
178 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase 1/2 Recruiting
155 enrolled
SURGE
Phase NA Recruiting
300 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Phase 2 Recruiting
49 enrolled
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Phase 1 Recruiting
180 enrolled
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Phase NA Recruiting
40 enrolled
RGL-305+ Lymphoma + Exploratory Clinical Study
Phase NA Recruiting
12 enrolled
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Phase 2 Recruiting
65 enrolled
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
248 enrolled